Novartis Ag

Other

Irm LLC

Keiichi Masuya

Pascal Furet

Philipp Holzer

Joerg Kallen

Stefan Stutz

Vito Guagnano

Andrea Vaupel

Takanori Kanazawa

Robert Mah

Achim Schlapbach

Fumiaki Yokokawa

Nicole Buschmann

Takahiro Miyake

Werner Breitenstein

Takeru Ehara

Philipp Grosche

Nils Ostermann

Ichiro Umemura

Edgar Jacoby

Carlos Garcia-Echeverria

Juergen Klaus Maibaum

Naoko Matsuura

Osamu Ohmori

Eiji Kawahara

Kazuhide Konishi

Claus Ehrhardt

Yuki Iwaki

Osamu Irie

Joerg Berghausen

Masaki Suzuki

Atsushi Toyao

Yuko Hitomi

Haixia Ren

Atsuko Iwasaki

Joanna Hergovich Lisztwan

Nathanael Schiander Gray

Donald Karanewsky

Guido Bold

Qiong Zhang

Yongqin Wan

Qiang Ding

Ruo W Steensma

Lv Liao

Joseph Schoepfer

Genji Iwasaki

Jiqing Jiang

Terance William Hart

Junichi Sakaki

Simona Cotesta

Andreas Marzinzik

Carole Pissot Soldermann

Liang Mao

Francois Gessier

Andreas Floersheimer

Naoki Teno

Greg Chopiuk

Masashi Kishida

Shimpei Kawakami

François Gessier

Juerg Zimmermann

Lorenz Mayr

Allan Hallett

Claus Erhardt

Jean-Marc Groell

Hajime Hirao

Andreas Boettcher

Atsuko Nihonyanagi

The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds. 

Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction

The invention relates to compounds of formula (I): (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of as MDM2 and/or MDM4, and combinations comprising such compounds. 

Substituted purinone compounds

The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.

Pyrrolopyrrolidinone compounds

The invention relates to substituted nitrogen containing bicyclic heterocycles of the formula (I) wherein Z is CHor N&#x2014;Rand X, R, R, R, R, Rand n are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.

Substituted isoquinolinones and quinazolinones

The invention relates to compounds of formula (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds. 

Pyrazolopyrrolidine compounds

The invention relates to compounds of formula (I): as defined in the application. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.

Cyclohexyl isoquinolinone compounds

The invention relates to compounds of formula (I): as defined in the application. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof. 

Hydroxy substituted isoquinolinone derivatives

Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases

Novel pyrimidine derivatives of formula I to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.

Pyrimidine derivatives

3,4-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4-substituted piperidine compound, and/or a method of treatment comprising administering a 3,4substituted piperidine compound, a method for the manufacture of a 3,4-substituted piperidine compound, and novel intermediates and partial steps for their synthesis are disclosed. The 3,4-disubstituted piperidine compounds have the formula (I), wherein the symbols have the meanings defined in the specification. 

Organic compounds

The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The preferred compounds (which can also be present as salts) have the formula I wherein R1, R2, T, R3 and R4 are as defined in the specification. 

3,4-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4-substituted piperidine compound, and/or a method of treatment comprising administering a 3,4-substituted piperidine compound, a method for the manufacture of a 3,4-substituted piperidine compound, and novel intermediates and partial steps for their synthesis are disclosed. The 3,4-disubstituted piperidine compounds have the formula I, 

The invention relates to 3-heterocyclyl indolyl compounds of formula I capable of inhibiting the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively: wherein R, R, R, R, R, Y and Y are as defined in the specification. Due to their activity, the compounds are useful in the treatment of various disorders and diseases mediated by the activity of MDM2 and/or MDM4, or variants thereof, such as inflammatory or proliferative diseases or in the protection of cells.

3-imidazolyl-indoles for the treatment of proliferative diseases

Novel pyrimidine derivatives of formula I to process for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.

2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders

Growing community of inventors

Basel, Switzerland

Keiichi Masuya